Special Issues
Perfluorinated chemicals (PFCs), also known as PFAAs, can be found in commercial and industrial uses such as firefighting foams, package material coatings, nonstick cookware, waterproofing, and stain-proof fabrics. PFCs are all manmade and have unique properties such as repelling water, oil, and heat. They are very difficult to break down and persist in the environment. Small amounts of PFCs can dissolve in water and is a cause for concern for human exposure, especially in drinking water sources such as large public water systems and private wells. A recent health advisory has been issued by U.S. Environmental Protection Agency (EPA). Water utilities should notify customers if greater than 70 ppt (0.07 µg/L) PFOS or PFOA or a total for the two combined are detected in the water supply.
The United States is not the only country concerned about exposure to PFCs. In Europe, the twelfth meeting of the United Nations Persistent Organic Pollutants Review Committee was held in Rome in September 2016 to move the consideration of PFCs forward for further regulatory consideration. Rules developed under this framework will have global impact. This work will demonstrate the capability of the SmartPrep(r) Cartridge Extraction II System for the extraction of six PFCs in compliance with US EPA 537 or ISO 25101:2009 (1).
Solid phase extraction (SPE) is used to remove and concentrate the PFCs from water samples. In U.S. EPA method 537, a 0.5 g, 6-mL SPE cartridge containing styrene divinylbenzene (SDVB) sorbent phase is specified. The analysis is done using HPLC–MS/MS for a sensitive detection step.
After demonstrating that the system does not contribute background to the extraction step, the Method Detection Limits (MDL) were determined from seven samples run on the SmartPrep over a three day period. The MDL values for this method with this sample size and equipment are extremely low (Table I). They will be able to measure water samples at the U.S. Health Advisory level of 0.07 µg/L for PFOS or PFOA with MDLs of 0.004 and 0.002 respectively. The limit of quantitation (LOQ) is 0.013 µg/L for PFOS and 0.0076 µg/L for PFOA, which is acceptable for very low level determinations.
PFC compounds are becoming an increasingly important concern as research into health effects uncovers other related illnesses. As countries around the world move to regulate exposure through drinking water, reliable, and accurate measurement methods become critical.
Methods US EPA 537 and ISO 25101:2009 specify extraction and concentration with SPE and analysis using HPLC–MS/MS. Automation of the cartridge SPE step is important to ensure the best reproducibility with the least chance of contamination. It also ensures the efficient use of technician time through walk-away operation.
The Extraction of Perfluorinated Alkyl Acids (PFAAs) in Drinking Water Using Automated Cartridge SPE, AN1131610_01, available from www.horizontechinc.com .
16 Northwestern Drive, Salem, NH 03079
tel. (603) 893-3663
Website: www.horizontechinc.com
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.